A Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of PF-03882845 In Healthy Volunteers
A Phase 1, Double-Blind (Sponsor Open), Randomized, Placebo- Controlled, Parallel Group, Oral Multiple-Dose Trial to Evaluate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PF-03882845 in Healthy Volunteers
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
Florida
-
South Miami, Florida, Forenede Stater, 33143
- Pfizer Investigational Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs).
- Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
Exclusion Criteria:
- Evidence or history of clinically significant disease.
- Past medical history of epididymitis, orchitis, sexually transmitted diseases (chlamydia, gonorrhea, etc.) or urinary tract infection.
- History of prostatitis or prostate surgery.
- Urinary catheterization or instrumentation within 12 months of screening. Inguinal or scrotal hernia.
- Current or history of congenital genital abnormalities.
- Baseline scrotal ultrasound scan showing unilateral or bilateral scrotal blood flow abnormalities or anatomic abnormalities (hydrocele, cysts, other), with the exception of small epididymal cysts and spermatoceles.
- Any condition possibly affecting drug absorption (eg, gastrectomy).
- Blood donation of approximately 1 pint (500 mL) within 56 days prior to dosing.
- History of sensitivity to spironolactone, eplerenone, or related compounds.
- Serum potassium >5.5 mEq/L at screening or Day 0.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Cohort 1
Healthy volunteers - PF-03882845 versus Placebo
|
PF-03882845 20 mg or Placebo, daily for 10 days.
PF-03882845 60 mg or Placebo, daily for 10 days.
PF-03882845 120 mg or Placebo, daily for 10 days.
PF-03882845 185 mg or Placebo, daily for 10 days.
|
|
Eksperimentel: Cohort 2
Healthy volunteers - PF-03882845 versus Placebo
|
PF-03882845 20 mg or Placebo, daily for 10 days.
PF-03882845 60 mg or Placebo, daily for 10 days.
PF-03882845 120 mg or Placebo, daily for 10 days.
PF-03882845 185 mg or Placebo, daily for 10 days.
|
|
Eksperimentel: Cohort 3
Healthy volunteers - PF-03882845 versus Placebo
|
PF-03882845 20 mg or Placebo, daily for 10 days.
PF-03882845 60 mg or Placebo, daily for 10 days.
PF-03882845 120 mg or Placebo, daily for 10 days.
PF-03882845 185 mg or Placebo, daily for 10 days.
|
|
Eksperimentel: Cohort 4
Healthy volunteers - PF-03882845 versus Placebo
|
PF-03882845 20 mg or Placebo, daily for 10 days.
PF-03882845 60 mg or Placebo, daily for 10 days.
PF-03882845 120 mg or Placebo, daily for 10 days.
PF-03882845 185 mg or Placebo, daily for 10 days.
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Single-Dose PK for PF-03382845: Cmax(ss), Tmax(ss), AUC(tau,ss), half life, Cmin(ss), Cave(ss), Ae%, CL/F, V/F, CL renal; accumulation ratios AUC(tau,ss)/AUC(tau,sd) and Cmax(ss)/Cmax(sd)
Tidsramme: 13 days
|
13 days
|
|
Safety and tolerability of PF-03382845 as determined by adverse event reporting, clinical laboratory results, vital signs (supine blood pressure and heart rate), physical examinations, electrocardiograms (ECGs) and potential sex hormone mediators.
Tidsramme: 13 days
|
13 days
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Area under the effect curve (AUEC) for serum aldosterone and PRA on Day 0 and on Days 1 and 10 after administration of PF-03882845
Tidsramme: 11 days
|
11 days
|
|
Change from baseline(Day 0) to Day8 in exploratory mRNA gene expression biomarkers (SGK1:Sodium-and Serum/glucocorticoid regulated kinase 1 gene,ENaCα:Epithelial Sodium Channel alpha subunit,ENaCγ:Epithelial Sodium Channel gamma
Tidsramme: 9 days
|
9 days
|
|
subunit,MR: Mineral corticoid Receptor,ACTβ:Beta Actin) after administration of PF-03882845 or placebo.These results will not be included in the study report
Tidsramme: 9 days
|
9 days
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- B0171008
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .